Intravenous Cisplatin, Doxorubicin, and Cyclophosphamide in the Treatment of Uterine Papillary Serous Carcinoma (UPSC)

Fredric V. Price, Setsuko K Chambers, Maria Luisa Carcangiu, Ernest I. Kohorn, Peter E. Schwartz, Joseph T. Chambers

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Thirty patients with uterine papillary serous carcinoma were treated with intravenous cisplatin, doxorubicin, and cyclophosphamide (CAP) chemotherapy, a combination with proven efficacy against ovarian carcinoma. Nineteen patients were given CAP as an adjuvant soon after surgery. Eleven patients were treated after recurrence or failure of other first-line therapy. Of the patients treated adjuvantly, 11 (58%) were alive without evidence of disease with a median follow-up of 24 months. Eight patients (42%), all with metastatic disease at diagnosis, were dead of disease (DOD) with a median survival of 14 months. In the salvage group, all patients were DOD with a median survival of 21 months from diagnosis and a median survival from initiation of CAP of 7 months. Toxicity was observed in all patients, and there was one treatment-related death from cardiotoxicity. In the salvage group there were two partial responses and one complete response (response rate = 27%). We conclude that intravenous CAP was ineffective in the treatment of metastatic or recurrent uterine papillary serous carcinoma, but deserves study as an adjuvant in patients without metastatic or with only microscopic extrauterine disease.

Original languageEnglish (US)
Pages (from-to)383-389
Number of pages7
JournalGynecologic Oncology
Volume51
Issue number3
DOIs
StatePublished - Dec 1993
Externally publishedYes

Fingerprint

Papillary Carcinoma
Doxorubicin
Cyclophosphamide
Cisplatin
Therapeutics
Survival
Combination Drug Therapy
Carcinoma
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Intravenous Cisplatin, Doxorubicin, and Cyclophosphamide in the Treatment of Uterine Papillary Serous Carcinoma (UPSC). / Price, Fredric V.; Chambers, Setsuko K; Carcangiu, Maria Luisa; Kohorn, Ernest I.; Schwartz, Peter E.; Chambers, Joseph T.

In: Gynecologic Oncology, Vol. 51, No. 3, 12.1993, p. 383-389.

Research output: Contribution to journalArticle

Price, Fredric V. ; Chambers, Setsuko K ; Carcangiu, Maria Luisa ; Kohorn, Ernest I. ; Schwartz, Peter E. ; Chambers, Joseph T. / Intravenous Cisplatin, Doxorubicin, and Cyclophosphamide in the Treatment of Uterine Papillary Serous Carcinoma (UPSC). In: Gynecologic Oncology. 1993 ; Vol. 51, No. 3. pp. 383-389.
@article{1bb66be96afa4d4592c929a3ad11bf11,
title = "Intravenous Cisplatin, Doxorubicin, and Cyclophosphamide in the Treatment of Uterine Papillary Serous Carcinoma (UPSC)",
abstract = "Thirty patients with uterine papillary serous carcinoma were treated with intravenous cisplatin, doxorubicin, and cyclophosphamide (CAP) chemotherapy, a combination with proven efficacy against ovarian carcinoma. Nineteen patients were given CAP as an adjuvant soon after surgery. Eleven patients were treated after recurrence or failure of other first-line therapy. Of the patients treated adjuvantly, 11 (58{\%}) were alive without evidence of disease with a median follow-up of 24 months. Eight patients (42{\%}), all with metastatic disease at diagnosis, were dead of disease (DOD) with a median survival of 14 months. In the salvage group, all patients were DOD with a median survival of 21 months from diagnosis and a median survival from initiation of CAP of 7 months. Toxicity was observed in all patients, and there was one treatment-related death from cardiotoxicity. In the salvage group there were two partial responses and one complete response (response rate = 27{\%}). We conclude that intravenous CAP was ineffective in the treatment of metastatic or recurrent uterine papillary serous carcinoma, but deserves study as an adjuvant in patients without metastatic or with only microscopic extrauterine disease.",
author = "Price, {Fredric V.} and Chambers, {Setsuko K} and Carcangiu, {Maria Luisa} and Kohorn, {Ernest I.} and Schwartz, {Peter E.} and Chambers, {Joseph T.}",
year = "1993",
month = "12",
doi = "10.1006/gyno.1993.1308",
language = "English (US)",
volume = "51",
pages = "383--389",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Intravenous Cisplatin, Doxorubicin, and Cyclophosphamide in the Treatment of Uterine Papillary Serous Carcinoma (UPSC)

AU - Price, Fredric V.

AU - Chambers, Setsuko K

AU - Carcangiu, Maria Luisa

AU - Kohorn, Ernest I.

AU - Schwartz, Peter E.

AU - Chambers, Joseph T.

PY - 1993/12

Y1 - 1993/12

N2 - Thirty patients with uterine papillary serous carcinoma were treated with intravenous cisplatin, doxorubicin, and cyclophosphamide (CAP) chemotherapy, a combination with proven efficacy against ovarian carcinoma. Nineteen patients were given CAP as an adjuvant soon after surgery. Eleven patients were treated after recurrence or failure of other first-line therapy. Of the patients treated adjuvantly, 11 (58%) were alive without evidence of disease with a median follow-up of 24 months. Eight patients (42%), all with metastatic disease at diagnosis, were dead of disease (DOD) with a median survival of 14 months. In the salvage group, all patients were DOD with a median survival of 21 months from diagnosis and a median survival from initiation of CAP of 7 months. Toxicity was observed in all patients, and there was one treatment-related death from cardiotoxicity. In the salvage group there were two partial responses and one complete response (response rate = 27%). We conclude that intravenous CAP was ineffective in the treatment of metastatic or recurrent uterine papillary serous carcinoma, but deserves study as an adjuvant in patients without metastatic or with only microscopic extrauterine disease.

AB - Thirty patients with uterine papillary serous carcinoma were treated with intravenous cisplatin, doxorubicin, and cyclophosphamide (CAP) chemotherapy, a combination with proven efficacy against ovarian carcinoma. Nineteen patients were given CAP as an adjuvant soon after surgery. Eleven patients were treated after recurrence or failure of other first-line therapy. Of the patients treated adjuvantly, 11 (58%) were alive without evidence of disease with a median follow-up of 24 months. Eight patients (42%), all with metastatic disease at diagnosis, were dead of disease (DOD) with a median survival of 14 months. In the salvage group, all patients were DOD with a median survival of 21 months from diagnosis and a median survival from initiation of CAP of 7 months. Toxicity was observed in all patients, and there was one treatment-related death from cardiotoxicity. In the salvage group there were two partial responses and one complete response (response rate = 27%). We conclude that intravenous CAP was ineffective in the treatment of metastatic or recurrent uterine papillary serous carcinoma, but deserves study as an adjuvant in patients without metastatic or with only microscopic extrauterine disease.

UR - http://www.scopus.com/inward/record.url?scp=0027733830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027733830&partnerID=8YFLogxK

U2 - 10.1006/gyno.1993.1308

DO - 10.1006/gyno.1993.1308

M3 - Article

VL - 51

SP - 383

EP - 389

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -